Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anixa Biosciences IncANIX · Entity 6698 | Director | August 13, 2020 | August 17, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anixa Biosciences Inc
Report date August 13, 2020 · Filed August 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.68 · Expires 2030-08-13 | Direct | 30,000 |
Reported balance
After 2020-08-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-08-13 · Grant · Acquired 30,000 · Balance 30,000 F1: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2: The options vest and become exercisable in twelve (12) equal monthly installments beginning August 31, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.
F2: The options vest and become exercisable in twelve (12) equal monthly installments beginning August 31, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2020 Filed Aug 17, 2020 16:17 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001513162-20-000171 · primary_doc.xml · derivative · entry 1 Cavalier David · CIK 0001289783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-08-13 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning August 31, 2020. Read SEC document |
| October 23, 2019 Filed Oct 24, 2019 19:41 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001513162-19-000224 · primary_doc.xml · derivative · entry 1 Cavalier David · CIK 0001289783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-10-23 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning November 30, 2019. Read SEC document |
| April 29, 2019 Filed Apr 29, 2019 13:02 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 2,000 | $4.21 | $8,420.00 |
DisclosureSEC source: 0001513162-19-000115 · primary_doc.xml · nonDerivative · entry 1 Cavalier David · CIK 0001289783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| October 08, 2018 Filed Oct 9, 2018 19:22 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $5.29 | $0.00 |
DisclosureSEC source: 0001513162-18-000254 · primary_doc.xml · derivative · entry 1 Cavalier David · CIK 0001289783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-10-08 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2010 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning October 31, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.